COMP <GO>
RITM vs SBRA // REVENUE GROWTH (YOY)
Rithm Capital Corp. (NYSE) VS. Sabra Health Care REIT Inc. (NASDAQ) • 15-METRIC TALLY: RITM 3
— SBRA 6
▲ REVENUE GROWTH (YOY) LEADER: SBRA
LAST: $9.22 (-2.43%) • MKT CAP: $5.28B
revenue-growth
-6.70%
LAST: $20.35 (+3.20%) • MKT CAP: $5.04B
revenue-growth
25.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RITM VS. SBRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RITM | SBRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.20% | 5.50% | -3.30 | SBRA | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.00% | 6.96% | -24.96 | SBRA | /fcf-yield <GO> |
| Operating Margin | 15.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 12.40% | 43.60% | -31.20 | SBRA | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -6.70% | 25.40% | -32.10 | SBRA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 5.78% | -5.78 | SBRA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 6/9 | -3.00 | SBRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.9 | 53.3 | +5.60 | RITM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 27.0x | -18.40 | RITM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.28B | $5.04B | $239.2M | RITM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RITM REV | SBRA REV | RITM GROSS % | SBRA GROSS % | RITM FCF | SBRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.59B | $356.9M | — | — | -$1.50B | $348.6M |
| FY 2024 | $4.92B | $284.6M | — | — | -$2.41B | $310.5M |
| FY 2023 | $3.68B | $236.2M | — | — | $528.0M | $300.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RITM // BETA 1.00
SBRA // BETA —